FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular, to haematology, namely to treating patients with multiple myeloma administered treatment with the medical product Daratumumab. Method for determining antierythrocytic alloantibodies in patients with multiple myeloma in an indirect antiglobulin test using pretreatment of test erythrocytes includes pretreatment conducted using monoclonal antibodies anti-CD38 (F(ab′)2) taken in a volume ratio of 1:5 to the sample.
EFFECT: higher reliability of alloantibody screening assessment.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF COMPLETING CRYOPRESERVED ERYTHROCYTE RESERVE BASED ON IMMUNOHEMATOLOGICAL CRITERIA | 2019 |
|
RU2708631C1 |
| SUBCUTANEOUS INJECTION OF ANTI-CD38 ANTIBODIES | 2019 |
|
RU2782950C2 |
| METHOD FOR ASSESSING THE RISK OF FORMATION OF ANTI-HLA ANTIBODIES DURING TRANSFUSION OF BLOOD COMPONENTS | 2022 |
|
RU2793843C1 |
| METHOD FOR DETERMINING POSTTRANSPLANTATION CHIMERISM IN COURSE OF STUDY OF ABO SYSTEM ERYTHROCYTE ANTIGENS | 2020 |
|
RU2758064C1 |
| METHOD FOR PLATELET AUTOANTIBODY TEST | 2012 |
|
RU2488114C1 |
| SUBCUTANEOUS DOSING OF ANTI-CD38 ANTIBODIES | 2019 |
|
RU2810953C2 |
| METHOD FOR THE DIAGNOSIS OF ALLOIMMUNE THROMBOCYTOPENIA OF THE NEWBORN | 2015 |
|
RU2611348C1 |
| METHOD FOR DIAGNOSING ALLOIMMUNE THROMBOCYTOPENIA OF NEWBORNS | 2022 |
|
RU2817215C2 |
| COMPOSITIONS CONTAINING ANTIBODIES TO CD38 AND LENALIDOMIDE | 2013 |
|
RU2698911C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
